Security
Janux Therapeutics, Inc. Common Stock · JANX
JANXNASDAQCommon stockCurrentCIK 1817713Updated Nov 6, 2026
JANX price & chart
Loading TradingView…
NASDAQ:JANX on TradingView ↗About the company
Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux’s lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA-TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007 and being evaluated in a Phase 1 clinical trial.
In the news
No coverage from other publishers is available.
Seeking Alpha
Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript ↗
Janux Therapeutics GAAP EPS of -$0.34 beats by $0.14, revenue of $9.29M beats by $2.87M ↗
SEC disclosures
Janux Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Janux Therapeutics, Inc.
SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Janux Therapeutics, Inc.
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,024,766,000Source | 695,019,000Source | 1,007,653,000Source | 1,032,212,000Source | 691,412,000Source | 1,028,225,000Source | 1,050,772,000Source | 688,984,000Source | 1,001,565,000Source | 1,061,516,000Source | 380,407,000Source | 364,010,000Source |
| Property, Plant and Equipment, NetUSD | 4,314,000Source | 5,373,000Source | 3,260,000Source | 4,688,000Source | 5,940,000Source | 3,546,000Source | 4,947,000Source | 6,517,000Source | 3,852,000Source | 4,864,000Source | 7,003,000Source | 7,086,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 48,389,000Source | 26,754,000Source | 27,768,000Source | 52,446,000Source | 14,662,000Source | 51,828,000Source | 73,743,000Source | 212,803,000Source | 52,334,000Source | 430,605,000Source | 19,205,000Source | 51,426,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | 7,500,000Source | — | — | 519,000Source | — | — | 0Source | 0Source |
| Assets, CurrentUSD | 998,086,000Source | 666,321,000Source | 983,337,000Source | 1,005,553,000Source | 661,939,000Source | 1,002,049,000Source | 1,023,339,000Source | 658,666,000Source | 975,887,000Source | 1,033,666,000Source | 349,241,000Source | 332,439,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,093,000Source | 8,290,000Source | 12,275,000Source | 9,542,000Source | 8,146,000Source | 10,663,000Source | 9,193,000Source | 6,384,000Source | 9,320,000Source | 8,493,000Source | 5,213,000Source | 5,423,000Source |
| Operating Lease, Right-of-Use AssetUSD | 18,923,000Source | 19,686,000Source | 17,327,000Source | 18,462,000Source | 20,077,000Source | 17,870,000Source | 18,878,000Source | 20,461,000Source | 18,402,000Source | 19,286,000Source | 20,838,000Source | 22,279,000Source |
| Other Assets, NoncurrentUSD | 2,627,000Source | 2,823,000Source | 2,913,000Source | 2,693,000Source | 2,640,000Source | 3,944,000Source | 2,792,000Source | 2,524,000Source | 2,608,000Source | 2,884,000Source | 2,509,000Source | 1,390,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 48,211,000Source | 38,915,000Source | 79,669,000Source | 41,696,000Source | 33,735,000Source | 86,690,000Source | 38,303,000Source | 33,221,000Source | 44,743,000Source | 38,735,000Source | 36,058,000Source | 43,270,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 60,000Source | 52,000Source | 61,000Source | 59,000Source | 52,000Source | 60,000Source | 59,000Source | 51,000Source | 60,000Source | 59,000Source | 46,000Source | 42,000Source |
| Retained Earnings (Accumulated Deficit)USD | -319,436,000Source | -217,541,000Source | -397,715,000Source | -295,123,000Source | -189,482,000Source | -375,743,000Source | -261,265,000Source | -183,523,000Source | -351,382,000Source | -237,757,000Source | -168,763,000Source | -110,470,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,562,000Source | 7,831,000Source | -2,305,000Source | 3,747,000Source | -1,616,000Source | 576,000Source | 3,756,000Source | -524,000Source | 4,316,000Source | 2,163,000Source | 665,000Source | -1,535,000Source |
| Stockholders' Equity Attributable to ParentUSD | 976,555,000Source | 656,104,000Source | 927,984,000Source | 990,516,000Source | 657,677,000Source | 941,535,000Source | 1,012,469,000Source | 655,763,000Source | 956,822,000Source | 1,022,781,000Source | 344,349,000Source | 320,740,000Source |
| Additional Paid in Capital, Common StockUSD | 1,291,369,000Source | 865,762,000Source | 1,327,943,000Source | 1,281,833,000Source | 848,723,000Source | 1,316,642,000Source | 1,269,919,000Source | 839,759,000Source | 1,303,828,000Source | 1,258,316,000Source | 512,401,000Source | 432,703,000Source |
| Liabilities and EquityUSD | 1,024,766,000Source | 695,019,000Source | 1,007,653,000Source | 1,032,212,000Source | 691,412,000Source | 1,028,225,000Source | 1,050,772,000Source | 688,984,000Source | 1,001,565,000Source | 1,061,516,000Source | 380,407,000Source | 364,010,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 27,831,000Source | 17,173,000Source | 60,152,000Source | 21,379,000Source | 11,545,000Source | 58,915,000Source | 17,502,000Source | 10,609,000Source | 24,997,000Source | 17,459,000Source | 13,033,000Source | 16,507,000Source |
| Operating Lease, Liability, CurrentUSD | 2,280,000Source | 1,689,000Source | 2,552,000Source | 1,873,000Source | 1,630,000Source | 2,472,000Source | 1,811,000Source | 1,573,000Source | 2,393,000Source | 1,749,000Source | 1,517,000Source | 763,000Source |
| Accounts Payable, CurrentUSD | 3,395,000Source | 2,462,000Source | 3,017,000Source | 3,477,000Source | 1,253,000Source | 3,376,000Source | 2,351,000Source | 2,254,000Source | 4,971,000Source | 4,026,000Source | 2,424,000Source | 2,159,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,380,000Source | 21,742,000Source | 18,438,000Source | 20,317,000Source | 22,190,000Source | 19,099,000Source | 20,801,000Source | 22,612,000Source | 19,746,000Source | 21,276,000Source | 23,025,000Source | 24,542,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 22,156,000Source | 13,022,000Source | 19,513,000Source | 16,029,000Source | 8,568,000Source | 15,476,000Source | 13,340,000Source | 5,810,000Source | 17,633,000Source | 11,684,000Source | 7,387,000Source | 8,010,000Source |
| Short-term InvestmentsUSD | 940,604,000Source | 631,277,000Source | 943,145,000Source | 943,565,000Source | 631,631,000Source | 904,558,000Source | 940,403,000Source | 438,960,000Source | 914,233,000Source | 594,568,000Source | 324,823,000Source | 275,590,000Source |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -24,313,000Source | -28,059,000Source | -21,972,000Source | -33,858,000Source | -24,361,000Source | -23,508,000Source | -113,625,000Source | -68,994,000Source | -58,293,000Source | -63,059,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 9,044,000Source | 15,387,000Source | 9,062,000Source | 10,960,000Source | 9,269,000Source | 10,702,000Source | 40,221,000Source | 33,020,000Source | 20,005,000Source | 17,203,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 35,000,000Source | 0Source | — | — | — | 0Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,612,000Source | -1,637,000Source | 977,000Source | 1,584,000Source | 277,000Source | -294,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,337,000Source | -17,024,000Source | -82,235,000Source | -43,814,000Source | -50,575,000Source | -42,922,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 8,286,000Source | -340,392,000Source | -300,981,000Source | -258,021,000Source | -41,194,000Source | 58,266,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 273,000Source | 371,000Source | 1,043,000Source | 359,000Source | 1,850,000Source | 6,445,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,545,000Source | 554,000Source | 4,945,000Source | 713,235,000Source | 59,548,000Source | 500,000Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | 469,000Source | 519,000Source | 2,029,000Source | 2,060,000Source | 1,955,000Source | 841,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 10,622,000Source | 17,667,000Source | 10,963,000Source | 10,454,000Source | 11,133,000Source | 9,842,000Source | 41,771,000Source | 41,047,000Source | 26,140,000Source | 22,262,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,313,000Source | -28,059,000Source | -21,972,000Source | -33,858,000Source | -24,361,000Source | -23,508,000Source | -113,625,000Source | -68,994,000Source | -58,293,000Source | -63,059,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,938,000Source | 7,783,000Source | 9,718,000Source | 11,260,000Source | 9,852,000Source | 11,389,000Source | 44,042,000Source | 29,853,000Source | 14,686,000Source | 4,032,000Source |
| Operating Costs and ExpensesUSD | — | — | 45,251,000Source | 36,281,000Source | 41,957,000Source | 45,118,000Source | 37,946,000Source | 34,897,000Source | 167,667,000Source | 109,435,000Source | 81,062,000Source | 75,703,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 10,000,000Source | 439,000Source | 10,267,000Source | 0Source | 3,733,000Source | 0Source | 10,000,000Source | 10,588,000Source | 8,083,000Source | 8,612,000Source |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -35,251,000Source | -35,842,000Source | -31,690,000Source | -45,118,000Source | -34,213,000Source | -34,897,000Source | -157,667,000Source | -98,847,000Source | -72,979,000Source | -67,091,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,313,000Source | -28,059,000Source | -21,972,000Source | -33,858,000Source | -24,361,000Source | -23,508,000Source | -113,625,000Source | -68,994,000Source | -58,293,000Source | -63,059,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.39Source | -0.51Source | -0.35Source | -0.55Source | -0.39Source | -0.38Source | -1.83Source | -1.28Source | -1.32Source | -1.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.39Source | -0.51Source | -0.35Source | -0.55Source | -0.39Source | -0.38Source | -1.83Source | -1.28Source | -1.32Source | -1.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 62,023,685Source | 54,628,670Source | 62,937,295Source | 61,902,411Source | 62,665,717Source | 61,791,721Source | 61,966,999Source | 53,751,480Source | 44,016,283Source | 41,469,631Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 62,023,685Source | 54,628,670Source | 62,937,295Source | 61,902,411Source | 62,665,717Source | 61,791,721Source | 61,966,999Source | 53,751,480Source | 44,016,283Source | 41,469,631Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,622,000Source | 17,667,000Source | 10,963,000Source | 10,454,000Source | 11,133,000Source | 9,842,000Source | 41,771,000Source | 41,047,000Source | 26,140,000Source | 22,262,000Source |
| Interest and Other IncomeUSD | — | — | 10,938,000Source | 7,783,000Source | 9,718,000Source | 11,260,000Source | 9,852,000Source | 11,389,000Source | 44,042,000Source | 29,853,000Source | 14,686,000Source | 4,032,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,938,000Source | 7,783,000Source | 9,718,000Source | 11,260,000Source | 9,852,000Source | 11,389,000Source | 44,042,000Source | 29,853,000Source | 14,686,000Source | 4,032,000Source |
| Operating Costs and ExpensesUSD | — | — | 45,251,000Source | 36,281,000Source | 41,957,000Source | 45,118,000Source | 37,946,000Source | 34,897,000Source | 167,667,000Source | 109,435,000Source | 81,062,000Source | 75,703,000Source |
| Research and Development ExpenseUSD | — | — | 34,629,000Source | 18,614,000Source | 30,994,000Source | 34,664,000Source | 26,813,000Source | 25,055,000Source | 125,896,000Source | 68,388,000Source | 54,922,000Source | 53,441,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 10,000,000Source | 439,000Source | 10,267,000Source | 0Source | 3,733,000Source | 0Source | 10,000,000Source | 10,588,000Source | 8,083,000Source | 8,612,000Source |
Filing attachments
janx-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights • Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026 • First patient dosed in the Phase 1 study evaluating JANX013 in combination with JANX007 • JANX007 Phase 1b development continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients wi…
Read attachment ↗janx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 janx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) • JANX011 Phase 1 healthy volunteer study progressing as planned • JANX013 remains on track for clinical initiation in th…
Read attachment ↗janx-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 janx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights • JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide • Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate • JANX011 Phase 1 study ongoing in healthy volunteers • Discontinued development of JANX008 following completion of Phase 1a • Achieved…
Read attachment ↗d12151071_ex99-1.htm · SCHEDULE 13G · 2026-04-29
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗d12151071_ex99-1.htm · SCHEDULE 13G · 2026-04-29
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗janx-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 janx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights • Continued clinical execution across TRACTr programs JANX007 and JANX008 • JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) • JANX008 enrolling expansion cohorts in defined tumor settings • Initiated Phase 1 study of JANX011 in healthy volunteers • Entered…
Read attachment ↗